z-logo
Premium
Self‐Assembly Protein Nanogels for Safer Cancer Immunotherapy
Author(s) -
Purwada Alberto,
Tian Ye F.,
Huang Weishan,
Rohrbach Kathleen M.,
Deol Simrita,
August Avery,
Singh Ankur
Publication year - 2016
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201501062
Subject(s) - cancer immunotherapy , immunotherapy , antigen , immune system , nanogel , limiting , safer , immunogenicity , toxicity , cancer research , medicine , immunology , materials science , nanotechnology , drug delivery , computer science , mechanical engineering , computer security , engineering
Soluble antigen‐based cancer vaccines have poor retention in tissues along with suboptimal antigen processing by dendritic cells. Multiple booster doses are often needed, leading to dose‐limiting systemic toxicity . A versatile, immunomodulatory, self‐assembly protein nanogel vaccine is reported that induces robust immune cell response at lower antigen doses than soluble antigens, an important step towards biomaterials‐based safer immunotherapy approaches.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here